Non-small cell lung carcinoma is a particularly aggressive type of lung cancer. Tumor cells and tumor DNA (ctDNA) in the blood of patients with the disease can be analyzed by means of liquid biopsy throughout the course of the disease. This information is important in order to be able to target the constantly changing tumor. A study from the University of Bayreuth is the first to show that liquid biopsy significantly improves treatment outcomes in many cases and can be cost-effective in the German care system. The scientists present their research results in the Journal of Cancer Research and Clinical Oncology.